Drug Interaction of Tofashine 5mg Tablet
Abatacept + Tofacitinib
The combination of this drug either increases the toxicity of the others by immunosuppressive effects. Use alternative drugs because the use of this drug may increase the risk of infections.
Atazanavir + Tofacitinib
Atazanavir increases the level of tofacitinib by affecting hepatic and intestinal enzyme metabolism. Use alternative drugs.
Cimetidine + Tofacitinib
Cimetidine increases the level of tofacitinib by decreasing its metabolism. Use alternative drugs.
Deferiprone + Tofacitinib
The combination of this drug either increases the toxicity of the others by pharmacodynamic synergism. Use alternative drugs because the use of this drug may increase the risk of neutropenia and agranulocytosis.
Fluconazole + Tofacitinib
Therapy should be administered with caution because the use of fluconazole increases the effect of tofacitinib by affecting its hepatic enzyme metabolism.
No information is available kindly consult with your doctor
The use of Tofashine tablet has been associated with viral reactivation including herpes viral reactivation. Before initiating the therapy it is recommended to screen for the reoccurrence of viral hepatitis.
Therapy should be administered with caution in patients with an increased risk of gastrointestinal perforation. Patients who are with new onset of abdominal symptoms should be evaluated for early identification of gastrointestinal perforation.
Tofashine tablet has not been studied in a patient with severe hepatic impairment and the use of tofacitinib has been associated with an increased risk of liver enzyme elevation. So it is recommended in patients with hepatic impairment. Routine monitoring of liver function tests is recommended.
Serious bacterial, mycobacterial, invasive fungal, viral and other opportunistic infections have been reported in patients who are all receiving tofacitinib. Before initiating the treatment it is recommended to avoid the use of tofacitinib in patients with an active and serious infection. Closely monitor the patient for the development of signs and symptoms of infection during and after treatment.
Patients with moderate and severe renal impairment had greater tofacitinib blood levels so the recommended dose of tofacitinib is 5 mg once daily. No dose adjustment of tofacitinib is necessary for patients with mild renal impairment.